203 related articles for article (PubMed ID: 30406916)
1. The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases.
Rinaldi S; Santoni M; Leoni G; Fiordoliva I; Marcantognini G; Meletani T; Armento G; Santini D; Newsom-Davis T; Tiberi M; Morgese F; Torniai M; Bower M; Berardi R
Support Care Cancer; 2019 Apr; 27(4):1255-1261. PubMed ID: 30406916
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Huang CY; Wang L; Feng CJ; Yu P; Cai XH; Yao WX; Xu Y; Liu XK; Zhu WJ; Wang Y; Zhou J; Lu Y; Wang YS
Oncotarget; 2016 Oct; 7(41):66480-66490. PubMed ID: 26624882
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.
Wu XT; Zhou JW; Pan LC; Ge T
J Int Med Res; 2020 May; 48(5):300060520925644. PubMed ID: 32425092
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy.
Sakin A; Sahin S; Yasar N; Demir C; Arici S; Geredeli C; Cihan S
Lung Cancer; 2019 Jul; 133():38-44. PubMed ID: 31200825
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
[TBL] [Abstract][Full Text] [Related]
8. The prognostic effects of hyponatremia and hyperchloremia on postoperative NSCLC patients.
Li W; Chen X; Wang L; Wang Y; Huang C; Wang G; Du J
Curr Probl Cancer; 2019 Oct; 43(5):402-410. PubMed ID: 30685068
[TBL] [Abstract][Full Text] [Related]
9. Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?
Deberne M; Ropert S; Billemont B; Daniel C; Chapron J; Goldwasser F
BMC Cancer; 2014 Jun; 14():416. PubMed ID: 24913188
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.
Tiseo M; Buti S; Boni L; Mattioni R; Ardizzoni A
Lung Cancer; 2014 Oct; 86(1):91-5. PubMed ID: 25130081
[TBL] [Abstract][Full Text] [Related]
11. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy.
Berardi R; Santoni M; Newsom-Davis T; Caramanti M; Rinaldi S; Tiberi M; Morgese F; Torniai M; Pistelli M; Onofri A; Bower M; Cascinu S
Oncotarget; 2017 Apr; 8(14):23871-23879. PubMed ID: 27863417
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.
Bae HM; Lee SH; Kim TM; Kim DW; Yang SC; Wu HG; Kim YW; Heo DS
Lung Cancer; 2012 Sep; 77(3):572-7. PubMed ID: 22672969
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis.
Xu Q; Wang Y; Liu H; Meng S; Zhou S; Xu J; Schmid-Bindert G; Zhou C
Clin Transl Oncol; 2013 Oct; 15(10):802-9. PubMed ID: 23430537
[TBL] [Abstract][Full Text] [Related]
14. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
[TBL] [Abstract][Full Text] [Related]
17. The influence of serum sodium concentration on prognosis in resected non-small cell lung cancer.
Kobayashi N; Usui S; Yamaoka M; Suzuki H; Kikuchi S; Goto Y; Sakai M; Sato Y
Thorac Cardiovasc Surg; 2014 Jun; 62(4):338-43. PubMed ID: 24297635
[TBL] [Abstract][Full Text] [Related]
18. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
[TBL] [Abstract][Full Text] [Related]
19. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer.
Willeumier JJ; van der Hoeven NM; Bollen L; Willems LN; Fiocco M; van der Linden YM; Dijkstra PD
Bone Joint J; 2017 Apr; 99-B(4):516-521. PubMed ID: 28385942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
